LifeVantage Corporation announced its financial results for the first quarter of fiscal 2027. Revenue during the period was $37.1 million, a 22% year-over-year decrease. Revenue in the Americas fell 22.2% to $29 million while revenue in the Asia/Pacific & Europe region fell 21.2% to $8.2 million. The company attributed this decline primarily to lower active accounts, reflecting impacts from the broader macro environment and lower sales of the MindBody GLP-1 System. These declines were partially offset, however, by sales of the LoveBiome product line, which LifeVantage acquired in October of 2025.

LifeVantage Corporation completed an in vitro research study examining the effects of modern environmental toxins, like pollution, microplastics, hormone disruptors and pesticides, on cellular health and the role Protandim Nrf2 can play in helping defend against their impact.

LifeVantage Corporation announced its financial results for the fourth fiscal quarter and full fiscal year 2026. Revenue during the fourth fiscal quarter was $42.4 million, down 23.1% year-over-year, with an adjusted EBITDA of $2.7 million. Net income per diluted share was $0.10, compared to $0.15 per diluted share in the year-ago period.

LifeVantage announced its financial results for the third fiscal quarter, ending March 31 2026. Gross profit during the quarter was $34.5 million, or 79% of revenue. This is a slight decrease from 81% of revenue in the same period of fiscal 2025, and is primarily due to an allowance for inventory obsolescence related to the MindBody GLP-1 System, as well as increased costs for shipping and warehousing. When adjusted for these considerations, gross profit was 79.4% of revenue.

LifeVantage Corporation has been granted a US Patent for the nutritional supplement composition and methods for activating cellular signaling genes of its Healthy Glow Essentials Stack. Within this stack are key activators Protandim Nrf2 Synergizer and TrueScience Liquid Collagen.

LifeVantage Corporation welcomed leaders for a three-day Momentum Academy event at Planet Hollywood Resort in Las Vegas, Nevada. Themed “Breakthrough,” the event offered product training, educational insights, networking opportunities and practical, actionable strategies to catalyze business growth.

LifeVantage Corporation announced it will expand its products and business opportunity to Portugal. The launch, planned for May 2026, is part of the company’s partnership with its field leadership as it expands and reinforces its commitment to deliver science-backed wellness solutions to consumers around the world.

Each year Stuart Johnson reviews the performance of the publicly traded product-centric direct selling companies. Because these companies report publicly, their results offer one of the clearest windows into the health of the channel.

LifeVantage Corporation announced its financial results for the second fiscal quarter, ending December 31, 2025. Revenue during this period was $48.9 million, up 2.9% sequentially, but down 27.8% year-over-year. Revenue in the Americas fells by 32.6% while revenue in Asia/Pacific and Europe saw relative stability with a 2.1% decline.

LifeVantage Corporation celebrated a successful Global Kickoff event that encouraged consultants worldwide to unlock new levels of leadership, impact and business growth. Themed “Breakthrough,” the virtual event was designed to set the tone for 2026, casting vision for a year of growth, innovation and momentum.

In a controlled, third-party in vitro study, LifeVantage Corporation’s proprietary P84 formula was shown to hold strong biological activity in cellular pathways linked to gut regulation, repair and restoration.

LifeVantage Corporation announced its financial results for the first quarter of fiscal 2026. Revenue during the period improved 0.7% year-over-year to $47.6 million. The Americas and Asia-Pacific & Europe regions saw revenue increases of 0.8% and 0.4% respectively.